rs137853859
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_001008216.2(GALE):c.505C>T(p.Arg169Trp) variant causes a missense change. The variant allele was found at a frequency of 0.000062 in 1,613,974 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000059 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000062 ( 0 hom. )
Consequence
GALE
NM_001008216.2 missense
NM_001008216.2 missense
Scores
11
5
3
Clinical Significance
Conservation
PhyloP100: 4.50
Genes affected
GALE (HGNC:4116): (UDP-galactose-4-epimerase) This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and cognitive disability, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.889
PP5
Variant 1-23797718-G-A is Pathogenic according to our data. Variant chr1-23797718-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 21171.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GALE | NM_001008216.2 | c.505C>T | p.Arg169Trp | missense_variant | 6/12 | ENST00000617979.5 | NP_001008217.1 | |
GALE | NM_000403.4 | c.505C>T | p.Arg169Trp | missense_variant | 6/12 | NP_000394.2 | ||
GALE | NM_001127621.2 | c.505C>T | p.Arg169Trp | missense_variant | 5/11 | NP_001121093.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GALE | ENST00000617979.5 | c.505C>T | p.Arg169Trp | missense_variant | 6/12 | 1 | NM_001008216.2 | ENSP00000483375 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000592 AC: 9AN: 152108Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
9
AN:
152108
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000716 AC: 18AN: 251474Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135916
GnomAD3 exomes
AF:
AC:
18
AN:
251474
Hom.:
AF XY:
AC XY:
8
AN XY:
135916
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000622 AC: 91AN: 1461866Hom.: 0 Cov.: 33 AF XY: 0.0000591 AC XY: 43AN XY: 727230
GnomAD4 exome
AF:
AC:
91
AN:
1461866
Hom.:
Cov.:
33
AF XY:
AC XY:
43
AN XY:
727230
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000592 AC: 9AN: 152108Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74296
GnomAD4 genome
AF:
AC:
9
AN:
152108
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74296
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
11
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:6Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
UDPglucose-4-epimerase deficiency Pathogenic:4Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 19, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 09, 2023 | - - |
not provided, no classification provided | literature only | GeneReviews | - | Account for 67% of alleles reported in a cohort of asymptomatic Koreans with peripheral epimerase deficiency galactosemia - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 07, 2022 | Variant summary: GALE c.505C>T (p.Arg169Trp) results in a non-conservative amino acid change located in the NAD(P)-binding domain (IPR016040) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7.2e-05 in 251474 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in GALE causing UDPglucose-4-Epimerase Deficiency (7.2e-05 vs 0.0011), allowing no conclusion about variant significance. c.505C>T has been reported in the literature in compound heterozygous individuals affected with peripheral/mild UDPglucose-4-Epimerase Deficiency (Park_2005, Tong_2016). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 60% of normal enzyme activity (Bang_2009). Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 16, 2023 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 169 of the GALE protein (p.Arg169Trp). This variant is present in population databases (rs137853859, gnomAD 0.05%). This missense change has been observed in individual(s) with epimerase deficiency galactosemia (PMID: 16301867, 28173647). ClinVar contains an entry for this variant (Variation ID: 21171). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GALE protein function with a negative predictive value of 80%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
See cases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Dec 06, 2019 | ACMG classification criteria: PS4, PM2, PM3, PP3 - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 11, 2014 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D;T;.;D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;.;D;D;.;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;M;.;.;.;.
MutationTaster
Benign
D
PrimateAI
Benign
T
PROVEAN
Pathogenic
.;D;D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
.;D;D;D;D;D
Sift4G
Pathogenic
D;D;.;D;.;D
Polyphen
D;D;.;.;.;.
Vest4
MutPred
Gain of catalytic residue at R169 (P = 0.1633);Gain of catalytic residue at R169 (P = 0.1633);.;.;Gain of catalytic residue at R169 (P = 0.1633);Gain of catalytic residue at R169 (P = 0.1633);
MVP
MPC
0.52
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at